Skip to main content
. 2015 Oct 8;10(10):e0140117. doi: 10.1371/journal.pone.0140117

Fig 3. Therapy protocol for DM-IP patients.

Fig 3

DM: dermatomyositis; IP: interstitial pneumonia; RPIP: rapidly progressive IP; CIP: chronic IP; MDA5: melanoma differentiation-associated gene 5; AaDO2: alveolar-arterial oxygen difference; PSL: prednisolone; CNI: calcineurin inhibitor; CSA: cyclosporine; C2: CSA level at 2 hours after administration; TAC: tacrolimus; IVCY: intravenous pulse cyclophosphamide; MMF: mycophenolate mofetil; IVIg: intravenous high-dose immunoglobulin; PE: plasma exchange; PMX-DHP: polymyxin B immobilized fiber column direct hemoperfusion; RTX; rituximab.